884495-16-3

Upstream product

• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 107-21-1 ethylene glycol 
• 624-28-2 2,5-dibromopyridine 
• 223463-13-6 2-iodo-5-bromopyridine 

Downstream Products

• 897943-14-5 2-[1,3]dioxolan-2-yl-5-phenylpyridine 
• 1264748-06-2 6,6′-diformyl-3,3′-bipyridine 
• 1309982-39-5 2-(1,3-dioxolan-2-yl)-5-pyridineboronic acid pinacol ester 
• 1214336-21-6 (3,4′-bipyridine)-6-carboxaldehyde 
• 1072952-38-5 (6-(1,3-dioxolan-2-yl)pyridin-3-yl)boronic acid 

Relevant academic research and scientific papers

Simultaneous Generation of a [2 × 2] Grid-Like Complex and a Linear Double Helicate: a Three-Level Self-Sorting Process

Two constitutional dynamic libraries (CDLs) - each containing two amines, two dialdehydes, and two metal salts - have been found to self-sort, generating two pairs of imine-based metallosupramolecular architectures (sharing no component) each with a [2 ×

Boronate Ester-Capped Helicates

Triple-stranded helicates were obtained by metal-templated multicomponent reactions of bispyridyloxime ligands with arylboronic acids. The helicates feature two hexa-coordinated MII ions (M=Fe, Zn, or Mn), which are embedded in a macrobicyclic ligand framework, and two arylboronate ester capping groups. The latter can be used to introduce functional groups such as pyridines, aldehydes, nitriles, and carboxylic acids in apical position. The functionalized helicates have the potential to be used as nanoscale building blocks for more complex assemblies, as evidenced by the synthesis of a 3 nm-sized trianglimine.

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

Luminescent Tetrahedral Molecular Cages Containing Ruthenium(II) Chromophores

We have designed linear metalloligands which contain a central photoactive [Ru(N∞N)3]2+ unit bordered by peripheral metal binding sites. The combination of these metalloligands with Zn(II) and Fe(II) ions leads to heterometallic tetrahedral cages, which were studied by NMR spectroscopy, mass spectrometry, and photophysical methods. Like the parent metalloligands, the cages remain emissive in solution. This approach allows direct incorporation of the favorable properties of ruthenium(II) polypyridyl complexes into larger self-assembled structures.

FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS

The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.

Stepwise construction of heterobimetallic cages by an extended molecular library approach

Two novel heterobimetallic complexes, a trigonal-bipyramidal and a cubic one, have been synthesized and characterized using the same C3-symmetric metalloligand, prepared by a simple subcomponent self-assembly strategy. Adopting the molecular library approach, we chose a mononuclear, preorganized iron(II) complex as the metalloligand capable of self-assembly into a trigonal-bipyramidal or a cubic aggregate upon coordination to cis-protected C2-symmetric palladium(II) or unprotected tetravalent palladium(II) ions, respectively. The trigonal-bipyramidal complex was characterized by NMR and UV-vis spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and single-crystal X-ray diffraction. The cubic structure was characterized by NMR and UV-vis spectroscopy and ESI-MS.

MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION

The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.

Perfluorinated ligands induce meridional metal stereochemistry to generate M8L12, M10L15, and M12L18 prisms

Meridional (mer) coordination promotes the generation of larger and lower-symmetry prismatic metallosupramolecular structures, in contrast with the facial (fac) coordination common to smaller and higher-symmetry polyhedra. Here, we describe a general route to the selective formation of large metallosupramolecular prisms that contain exclusively mer-coordinated metal vertices. The use of 2-formylpyridine subcomponents that contain perfluorophenylene substituents at their 5-positions resulted in stereoselective formation of the iron(II) complexes from these subcomponents. Only mer vertices were observed, as opposed to the statistical fac/mer mixture otherwise generated. This mer-selective self-assembly could be used to prepare tetragonal (M8L12), pentagonal (M10L15), and hexagonal (M12L18) prisms by taking advantage of the subtle selectivities imposed by the different anilines and counterions employed. The equilibrium between the tetragonal and pentagonal prism followed a linear free-energy relationship, with the ratio between structures correlating with the Hammett σp+ parameter of the incorporated aniline. The contrasting preferences of the fluorinated and nonfluorinated ligands to generate prisms and tetrahedra, respectively, were quantified energetically, with the destabilization increasing linearly for each "incorrect ligand" incorporated into either structure.

PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL INFARCTION

The object of the present invention is to provide a pharmaceutical composition for treating cerebral infarction. The present invention provides a pharmaceutical composition for treating cerebral infarction comprising a compound of formula (I) or a pharmac

Post-assembly modification of tetrazine-edged FeII4L6 tetrahedra

Post-assembly modification (PAM) is a powerful tool for the modular functionalization of self-assembled structures. We report a new family of tetrazine-edged FeII4L6 tetrahedral cages, prepared using different aniline subc